Heparin-coated Wiktor stents in human coronary arteries (MENTOR Trial)

Matty C M Vrolix, Victor M. Legrand, Johan H C Reiber, Gille Grollier, Martin J. Schalij, Philippe Brunel, Louis Martinez-Elbal, Manuel Gomez-Recio, Frits W H M Bär, Michel E. Bertrand, Antonio Colombo, Johannes Brachman

Research output: Contribution to journalArticlepeer-review


The purpose of this study was to determine the feasibility, safety, and efficacy of elective stenting with heparin-coated Wiktor stents in patients with coronary artery disease. In experimental studies, heparin coating has been shown to prevent subacute thrombosis and restenosis. Recently, a new method of heparin coating was developed, resulting in a more stable and predictable heparin layer on stent devices. This trial constitutes the first in-human use of this coating procedure, applied on the well-known Wiktor stent device. Heparin-coated Wiktor stent implantation was performed in 132 consecutive patients (132 lesions) in a multicenter international trial from September 1996 to February 1997. Forty-three percent of patients had unstable angina, 33% had previous myocardial infarction, and 10% had diabetes mellitus. Patients were followed for 12 months for occurrence of major adverse cardiovascular events, and 96% of the eligible patients underwent quantitative angiographic control at 6 months. Stent deployment was successful in 95.5% of lesions. Minimal lumen diameter increased by 1.67 ± 0.48 mm (from 1.02 ± 0.38 mm before to 2.69 ± 0.37 mm after the stent implantation). Mean percent diameter stenosis decreased from 67.4 ± 11.3% before to 18.9 ± 7.7% after the intervention. A successful intervention (<50% diameter stenosis and no major adverse cardiac events within 30 days) occurred in 97% of the patients. The subacute thrombosis rate was 0.8%, which compares favorably with historical controls of this stent, and a low incidence of postprocedural increase in creatine kinase-MB was noted. At 6 months, event-free survival was 85% and angiographic restenosis rate was 22% with late loss of 0.78 ± 0.69 mm and a loss index of 0.48 ± 0.44. Heparin-coated Wiktor stents appeared to be an efficacious device to treat Benestent-like lesions, yielding angiographic and clinical results comparable to a heparin-coated Palmaz-Schatz stent. Despite its use in more complex lesions, the incidence of subacute thrombosis appeared to be lower than historical controls with a similar noncoated stent. (C) 2000 by Excerpta Medica, Inc.

Original languageEnglish
Pages (from-to)385-389
Number of pages5
JournalThe American Journal of Cardiology
Issue number4
Publication statusPublished - Aug 15 2000

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Heparin-coated Wiktor stents in human coronary arteries (MENTOR Trial)'. Together they form a unique fingerprint.

Cite this